( OTC-PINK:ESALY )

News from morphotek, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 18, 2016, 10:00 ET Morphotek Announces Publication Of Phase 3 Results From MORAb-003-004 Trial In Platinum-Sensitive Ovarian Cancer Patients

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that results from the Phase 3 MORAb-003-004 trial were recently published...


Feb 03, 2016, 09:00 ET Morphotek Announces Collaboration with Mayo Clinic to Apply Its Folate Receptor Alpha Diagnostic Assays in a Phase II Clinical Trial in Triple-Negative Breast Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it is collaborating with researchers Keith L. Knutson, Ph.D. in the...


Dec 16, 2015, 09:00 ET Morphotek®, Inc. Announces An Agreement With Biocare Medical, LLC To Develop And Commercialize A Diagnostic Kit For Detection Of Mesothelin In Malignant Tissues

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a second collaboration and license agreement with...


Dec 16, 2015, 09:00 ET Morphotek®, Inc. Announces An Agreement With Biocare Medical, LLC To Develop And Commercialize A Diagnostic Kit For Detection Of Mesothelin In Malignant Tissues

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a second collaboration and license agreement with...


Dec 07, 2015, 09:00 ET Morphotek Announces Phase 1 Results From MORAb-022-001 Trial In Healthy Subjects And Patients With Mild-To-Moderate Rheumatoid Arthritis

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today results from Study MORAb-022-001, a single-dose, dose-ascending,...


Dec 07, 2015, 09:00 ET Morphotek Announces Phase 1 Results From MORAb-022-001 Trial In Healthy Subjects And Patients With Mild-To-Moderate Rheumatoid Arthritis

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today results from Study MORAb-022-001, a single-dose, dose-ascending,...


Dec 03, 2015, 09:00 ET Morphotek Announces Collaboration Agreement With University Of Wisconsin-Madison To Study The Immunosuppressive Effects Of CA125 Tumor Antigen On Immune-Based Therapies For Ovarian Cancer

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a collaborative research agreement with University of...


Dec 03, 2015, 09:00 ET Morphotek Announces Collaboration Agreement With University Of Wisconsin-Madison To Study The Immunosuppressive Effects Of CA125 Tumor Antigen On Immune-Based Therapies For Ovarian Cancer

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a collaborative research agreement with University of...


Nov 18, 2015, 09:00 ET Morphotek®, Inc. Announces Initiation Of Amatuximab Study In First-Line, Unresectable, Malignant Pleural Mesothelioma Patients

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in the randomized, double-blind...


Nov 17, 2015, 09:00 ET Morphotek Announces Collaboration Agreement With University of Gothenburg To Develop Farletuzumab, An Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, For Alpha-Particle Radioimmunotherapy In Ovarian Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into an agreement with the Targeted Alpha Therapy Group...


Nov 09, 2015, 09:00 ET Morphotek®, Inc. Announces A License Agreement With Blaze Bioscience, Inc. For The Development Of Novel Oncology Imaging Technology

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of...


Mar 30, 2015, 09:00 ET Morphotek®, Inc. Announces Initiation Of Farletuzumab Study In Patients With First-Relapsed, Platinum-Sensitive Ovarian Cancer With Low Levels Of The Immunosuppressive CA125 Tumor Antigen

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in a randomized, double-blind study of...